QDEL has been the topic of several other reports. Citigroup upgraded shares of QuidelOrtho from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $90.00 to $125.00 in a report on Monday, December 12th. Craig Hallum reduced their price objective on shares of QuidelOrtho to $173.00 in a report on Wednesday, December 14th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of QuidelOrtho from $100.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, November 3rd. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, QuidelOrtho has a consensus rating of “Moderate Buy” and a consensus price target of $123.83.
Institutional Trading of QuidelOrtho
Institutional investors and hedge funds have recently bought and sold shares of the business. Truist Financial Corp boosted its holdings in shares of QuidelOrtho by 52.1% in the fourth quarter. Truist Financial Corp now owns 12,253 shares of the company’s stock valued at $1,050,000 after acquiring an additional 4,198 shares during the period. Linden Thomas Advisory Services LLC acquired a new stake in shares of QuidelOrtho in the fourth quarter valued at approximately $1,123,000. State of Wyoming boosted its holdings in shares of QuidelOrtho by 23.5% in the fourth quarter. State of Wyoming now owns 5,520 shares of the company’s stock valued at $473,000 after acquiring an additional 1,050 shares during the period. Lazard Asset Management LLC boosted its holdings in shares of QuidelOrtho by 4.2% in the fourth quarter. Lazard Asset Management LLC now owns 494,877 shares of the company’s stock valued at $42,396,000 after acquiring an additional 20,159 shares during the period. Finally, Gamco Investors INC. ET AL boosted its holdings in shares of QuidelOrtho by 2.0% in the fourth quarter. Gamco Investors INC. ET AL now owns 194,746 shares of the company’s stock valued at $16,684,000 after acquiring an additional 3,792 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.
QuidelOrtho Price Performance
The firm has a market capitalization of $6.04 billion, a price-to-earnings ratio of 7.37 and a beta of 0.27. The company has a fifty day moving average price of $86.45 and a two-hundred day moving average price of $84.78. The company has a quick ratio of 1.04, a current ratio of 1.66 and a debt-to-equity ratio of 0.52.
About QuidelOrtho
(Get Rating)
QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.
Further Reading
Receive News & Ratings for QuidelOrtho Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for QuidelOrtho and related companies with MarketBeat.com’s FREE daily email newsletter.